drugset / Trial / NCT04072562

A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.

NCT04072562

Phase 1 Completed 24 enrolled AstraZeneca Parexel · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the relative bioavailability of the AZD7594 nebulized formulations (test) and the dry powder formulation (reference). The study results will provide information on the pharmacokinetic (PK) profile following use of the 2 devices to be used in further clinical development.

Timeline

Start
2019-09-19
Primary completion
2019-11-28
Completion
2019-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject VELSECORAT Other / unclassified 0.7 mg Inhaled
Subject VELSECORAT Other / unclassified 720 ug Inhaled
Subject VELSECORAT Other / unclassified 1.6 mg Inhaled

Indications